Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd ed. New York, NY: Cambridge University Press (2008).
Janicak PG, et al. (2008). Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry, 69(2):222-232.
Data on file. Neuronetics, Inc.
O’Reardon JP, et al. (2007). Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry, 62(11):1208-1216.
George MS, et al. (2010). Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry, 67(5):507-516.
Carpenter LL, et al. (2012). Transcranial magnetic stimulation (TMS) for major depression: a multisite naturalistc, observational study of acute treatment outcomes in clinical practice. Depress Anxiety, 29(7):587-596.
Avery DH, et al. (2008). Transcranial Magnetic Stimulation in the acute treatment of major depressive disorder: clinical response in an open-label extension trial. J Clin Psychiatry, 69(3):441-451.
McDonald WM, et al. (2011). Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress Anxiety, 28(11):973-980.
Janicak PG, et al. (2010). Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimulation, 3(4):187-199.
Demitrack MA, Thase ME. (2009). Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull, 42(2):5-38.